secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001104659-22-126489
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Priveterra (PMGM) enters definitive merger with AEON Biopharma at $165M equity value
--------------------------------------------------------------------------------

- Implied AEON equity value of $165M; AEON stockholders to receive Priveterra Class A common shares.
- Up to 16M earnout shares tied to FDA milestones: Phase 3 migraine start, BLA acceptance for cervical dystonia and migraine.
- Bridge financing: up to $20M from AEON stockholders; $4M bridge if Closing not by March 1, 2023; $8M sponsor bridge if S-4 not effective by April 1, 2023.
- Closing condition: minimum $45M available cash after redemptions, stockholder approvals, Nasdaq listing, and HSR clearance.
- Sponsor (3.45M Contingent Founder Shares) and AEON stockholders subject to 1-year lock-up; early release at $12.50/$15.00 VWAP thresholds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/0001104659-22-126489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/tm2232428d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer